<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Sgrignani, Jacopo</dc:creator>
  <dc:creator>Garofalo, Maura</dc:creator>
  <dc:creator>Matkovic, Milos</dc:creator>
  <dc:creator>Merulla, Jessica</dc:creator>
  <dc:creator>Catapano, Carlo V.</dc:creator>
  <dc:creator>Cavalli, Andrea</dc:creator>
  <dc:date>2018-05-28</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Transcription factors are proteins able to bind DNA and induce the transcription of specific  genes. Consequently, they play a pivotal role in multiple cellular pathways and are frequently  over-expressed or dysregulated in cancer. Here, we will focus on a specific “signal  transducer and activator of transcription” (STAT3) factor that is involved in several  pathologies, including cancer. For long time, the mechanism by which STAT3 exerts its  cellular functions has been summarized by a three steps process: (1) Protein  phosphorylation by specific kinases, (2) dimerization promoted by phosphorylation, (3)  activation of gene expression by the phosphorylated dimer. Consequently, most of the  inhibitors reported in literature aimed at blocking phosphorylation and dimerization. However,  recent observations reopened the debate and the entire functional mechanism has been  revisited stimulating the scientific community to pursue new inhibition strategies. In particular,  the dimerization of the unphosphorylated species has been experimentally demonstrated  and specific roles proposed also for these dimers. Despite difficulties in the expression and  purification of the full length STAT3, structural biology investigations allowed the  determination of atomistic structures of STAT3 dimers and several protein domains. Starting  from this information, computational methods have been used both to improve the  understanding of the STAT3 functional mechanism and to design new inhibitors to be used  as anticancer drugs. In this review, we will focus on the contribution of structural biology to  understand the roles of STAT3, to design new inhibitors and to suggest new strategies of  pharmacological intervention.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/318914</dc:identifier>
  <dc:identifier>https://n2t.net/ark:/12658/srd1318914</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/318914/files/Sgrignani_IJMS_2018.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms19061591</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1318914</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>International journal of molecular sciences. - 2018, vol. 19, no. 6, p. 1591</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">STAT3</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Cancer</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Molecular modeling</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Drug design</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Structural biology</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns6="xml" ns6:lang="en">Structural biology of STAT3 and its implications for anticancer therapies development</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
